In experimental animals, a single subcutaneous administration of up to 60 times the recommended human dose (on a mg/kg basis, not adjusted for bioavailability) had no adverse effects. At present, there is no clinical evidence of adverse effects following overdosage of GnRH analogs.

Based on studies in monkeys, SYNAREL is not absorbed after oral administration.

1. Hypersensitivity to GnRH, GnRH agonist analogs or any of the excipients in SYNAREL; 2. Undiagnosed abnormal vaginal bleeding; 3. Use in pregnancy or in women who may become pregnant while receiving the drug. SYNAREL may cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rats, but not in mice or rabbits after administration of SYNAREL during the period of organogenesis. There was a dose-related increase in fetal mortality and a decrease in fetal weight in rats (see Pregnancy Section). The effects on rat fetal mortality are expected consequences of the alterations in hormonal levels brought about by the drug. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus; 4. Use in women who are breast-feeding (see Nursing Mothers Section).

Bookmark this page: